top of page


The International Radiosurgery Oncology Consortium for Kidney (IROCK) collaborates on research into stereotactic ablative radiotherapy (SABR) for primary renal cell carcinoma (RCC). The primary purpose of the IROCK Registry is to evaluate the time between SABR treatment and recurrence (when cancer returns after treatment) that occurs in the area of the initial tumour, in patients with RCC. The secondary objective of the study will assess efficacy and survival outcomes.

The IROCK Registry is extremely grateful to the Lo's Family Charity Fund Limited

for providing the registry with secure funding for five years via a generous donation. 


The IROCK Registry database is housed and maintained by the Peter MacCallum Cancer Centre in Melbourne, Australia. Feel free to get in touch with the Registry Coordinator with questions or comments regarding the work of the registry.

bottom of page